Cullgen is a drug discovery services intended to create new drugs for the treatment of diseases that currently lack effective therapies.
Cullgen has raised $35.0M in total funding. The most recent round was Series C. The last funding was announced in May 2023.
Cullgen's investors include HSG, Highlight Capital, 3E Bioventures, Octagon Capital Advisors, MSA Capital.
Cullgen is headquartered in San Diego, United States.
Cullgen is a drug discovery services intended to create new drugs for the treatment of diseases that currently lack effective therapies.
Cullgen is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cullgen — Funding & Investors." VCBacked, May 8, 2023, https://www.vcbacked.co/company/cullgen. Accessed July 19, 2026.
VCBacked. (2023). Cullgen — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/cullgen
{{cite web |title=Cullgen — Funding & Investors |url=https://www.vcbacked.co/company/cullgen |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated